ONC013: A phase II, open-label study of ONC201 in adults with recurrent high-grade glioma
Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Sponsor: Chimerix, Inc & NIH
Enrolling: Male and Female Patients
IRB Number: AAAS1885
U.S. Govt. ID: NCT03295396
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
This study is closed
Investigator
Andrew Lassman, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with a high-grade glioma? Yes No
Has your disease progressed? Yes No
Have you undergone previous treatment with radiotherapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE